Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 8/20 | 0.35 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.33 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436002 | 0.93 | PTPN11 (0.40) | PTPN11BRD4HTR6MAP4K3L3MBTL1 | |
| SCHEMBL31436001 | 0.91 | PTPN11 (0.40) | PTPN11BRD4HTR6L3MBTL1 | |
| SCHEMBL31435908 | 0.91 | PTPN11 (0.41) | PTPN11BRD4HTR6PAK1MAP4K3 | |
| SCHEMBL31435990 | 0.90 | PTPN11 (0.39) | PTPN11BRD4HTR6PAK1MAP4K3 | |
| SCHEMBL31435923 | 0.84 | PTPN11 (0.40) | PTPN11BRD4HTR6L3MBTL1 | |
| SCHEMBL31435955 | 0.83 | PTPN11 (0.42) | PTPN11BRD4PAK1 | |
| SCHEMBL31435960 | 0.82 | PTPN11 (0.41) | PTPN11BRD4HTR6L3MBTL1JAK2 | |
| SCHEMBL31435904 | 0.82 | PTPN11 (0.39) | PTPN11BRD4HTR6L3MBTL1 | |
| SCHEMBL30365155 | 0.81 | PTPN11 (0.40) | PTPN11BRD4HTR6PAK1MAP4K3 | |
| SCHEMBL31435995 | 0.79 | PTPN11 (0.39) | PTPN11BRD4HTR6PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | PTPN11 65/4885BRD4 2456/4885HTR6 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.